Related references
Note: Only part of the references are listed.PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Eric Jay Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration
Naoki Terada et al.
INTERNATIONAL JOURNAL OF UROLOGY (2017)
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Wanling Xie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
Matthew R. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase 3, Randomized, Placebo-Controlled Study Of Zibotentan (ZD4054) in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone
Joel B. Nelson et al.
CANCER (2012)
Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer
Evan Y. Yu et al.
JOURNAL OF UROLOGY (2012)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R. Smith et al.
LANCET (2012)
Phase 3, Randomized, Controlled Trial of Atrasentan in Patients With Nonmetastatic, Hormone-Refractory Prostate Cancer
Joel B. Nelson et al.
CANCER (2008)
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical states in prostate cancer: Toward a dynamic model of disease progression
HI Scher et al.
UROLOGY (2000)
Share Paper
